Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients

Completed

Conditions studied: Multiple Sclerosis

In brief

Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.

Key facts

Study ID

NCT01399957

Run by

Mount Sinai Rehabilitation Hospital

People needed

52

Starts

2010-08-01

Expected to finish

2015-09-01

Last updated by the study team

2015-11-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed clinical diagnosis of MS by McDonald criteria
• Prescribed ampyra (dalfampridine) as part of usual care, but have not yet started taking the medication before baseline visit
• Receive MS care at the Mandell MS center
• Cognitively able to understand directions and complete protocol (score of 22 or greater on the MMSE)
• 18 years of age or older

You may not qualify if…

• Already began to take drug prior to baseline research visit
• Not planning to continue care at Mandell Center for at least 14 weeks after initiation of therapy
• Unwilling or unable to complete assessments

Where it is running

• Mandell Center for Multiple Sclerosis at the Mount Sinai Rehabilitation Hospital — Hartford, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.